Pulmonary embolism is the third most common cause of death from cardiovascular disease
after heart attack and stroke. Sequelae occurring after venous thromboembolism include …

Background: New treatments are available for treatment of venous thromboembolism.
Purpose: To review the evidence on the efficacy of interventions for treatment of deep …

This consensus document is proposed to clinicians to provide the whole spectrum of deep
vein thrombosis management as an update to the 2017 consensus document. New data …

To evaluate the role of low-molecular weight heparin (LMWH) as an alternative to oral
anticoagulants in the prevention of recurrent venous thromboembolism, we compared in a …

Purpose Over the past 20 years results of clinical trials have provided information that has
revolutionized the approach to management of venous thromboembolic disease. New …

We compared the efficacy and safety of low molecular weight heparins (LMWH) and
unfractionated heparin (UFH) in the treatement of deep venous thrombosis (DVT). A …

Importance Many anticoagulant strategies are available for the treatment of acute venous
thromboembolism, yet little guidance exists regarding which drug is most effective and safe …

Deep vein thrombosis and its sequelae pulmonary embolism and post-thrombotic syndrome
are some of the most common disorders. A thrombus either arises spontaneously or is …

All patients with venous thromboembolism (VTE) should receive anticoagulant treatment in
the absence of absolute contraindications. Initial anticoagulant treatment is crucial for …

Venous thromboembolism, including deep vein thrombosis and pulmonary embolism,
represents a significant source of morbidity and mortality in the United States and worldwide …